Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Reports suggest that roughly one in five peptide shipments from unverified Chinese suppliers arrives with documentation that does not match the actual product
As of June 2026, the FDA has not approved retatrutide for any indication
Developed by Eli Lilly, retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, setting it apart from existing licensed treatments such as semaglutide and tirzepatide
Sex was not considered as a biological variable, given the low percentage of males in our study population, consistent with the greater percentage of females among the post-surgical population, limiting power for sex-specific analysis
US$ 23.54
US$ 21.84
US$ 24.76
US$ 23.46
US$ 22.40
